|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 July 2007, Vol. 110, No. 1, pp. 4.
Gene therapy as salvageUNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Chinen and colleagues describe the outcome of gene therapy for 3 young adolescents with XSCID for whom prior attempts at allogeneic bone marrow transplant had failed to achieve significant immunologic reconstitution. Clear-cut clinical benefits have recently been obtained in multiple trials of gene therapy using hematopoietic stem cells (HSCs) for infants with XSCID and adenosine deaminase (ADA)-deficient SCID, and for young adults with chronic granulomatous disease (CGD). Thus, the debate over gene therapy has moved from "will it ever be beneficial?" to "when is it beneficial?" Studies are moving forward exploring the use of gene-corrected autologous HSCs in treating other immune deficiencies (eg, Wiskott-Aldrich syndrome), hemoglobinopathies, leukodystrophies, and mucopolysaccharidoses, as well as multiple applications to oncological diseases.
The cohort of preteens with X-linked SCID (XSCID) reported by Chinen and colleagues was unique in that each had undergone haploidentical, T-cell–depleted bone marrow transplantation without cytoreductive conditioning during infancy.2 Despite this, they were chronically ill for a decade or longer, due to minimally corrected immune function and, possibly, chronic graft-versus-host disease (GVHD). There were no further conventional allogeneic HSC transplantation (HSCT) options to restore immunity, and thus they underwent gene therapy, weighing potential benefits from immune restoration with the risks of a T-lymphoproliferative disorder seen to date in 4 XSCID infants.3 A retroviral vector carrying a normal human One of the 3 patients had evidence of some immunologic improvement, with increased production of T lymphocytes (approximately 2-fold increase in the absolute number of T cells and increased levels of naive T cells). Because SCID patients failing to achieve immune reconstitution after HSCT are in a desperate clinical situation, even this modest level of benefit may be relevant. However, the other 2 patients did not show any significant effects from the procedure and remained immune-deficient. Reconstitution of T lymphopoiesis may be primarily limited by poor thymic function in these older, chronically ill children, especially if they have prior maternal or transplant-related GVHD that can cause thymic damage.4 Gene therapy may prove to be better in this setting than additional attempts at haploidentical or matched unrelated allogeneic HSCT, if only in that there should be no risk of GVHD being caused or worsened by reinfusion of autologous HSCs. As gene therapy continues to improve in efficacy and safety, it may used up front as primary therapy for most SCID patients lacking matched sibling donors. If so, the emergence of further cohorts of patients who have not responded to allogeneic HSCT could be avoided. In the meantime, gene therapy may be a beneficial option for these unique patients as a salvage therapy.
Footnotes
Conflict-of-interest disclosure: The author declares no competing financial interests.
REFERENCES
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||
| |||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||
C cDNA was used to transduce their bone marrow CD34+ cells from autologous bone marrow, an approach similar to that used in the gene therapy trials for the XSCID infants. 
